BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Hong YS, Chang Y, Ryu S, Cainzos-Achirica M, Kwon MJ, Zhang Y, Choi Y, Ahn J, Rampal S, Zhao D, Pastor-Barriuso R, Lazo M, Shin H, Cho J, Guallar E. Hepatitis B and C virus infection and diabetes mellitus: A cohort study. Sci Rep 2017;7:4606. [PMID: 28676706 DOI: 10.1038/s41598-017-04206-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
2 Hong K, Kim N, Song S, Hong G. Cycling of Dexmedetomidine May Prevent Delirium After Liver Transplantation. Transplantation Proceedings 2018;50:1080-2. [DOI: 10.1016/j.transproceed.2017.11.076] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jeong Y, Jin B, Lee HW, Park HJ, Park JY, Kim DY, Han K, Ahn SH, Kim S. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures. J Viral Hepat 2018;25:1251-9. [DOI: 10.1111/jvh.12932] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
4 Kim BK, Jang ES, Kim JH, Park SY, Ahn SV, Kim HJ, Kim DY. Current status of and strategies for hepatitis C control in South Korea. Clin Mol Hepatol 2017;23:212-8. [PMID: 28942625 DOI: 10.3350/cmh.2017.0105] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
5 Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. Korean J Intern Med 2019;34:794-801. [PMID: 29792020 DOI: 10.3904/kjim.2017.368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Yu JH, Kim JK, Lee KS, Lee JI. Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment. J Clin Gastroenterol 2018;52:557-62. [PMID: 28863014 DOI: 10.1097/MCG.0000000000000923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology. 2019;. [PMID: 31556128 DOI: 10.1002/hep.30973] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
8 Lee BS, Song MJ, Kwon JH, Lee TH, Jang JW, Kim SH, Lee SH, Kim HS, Kim JH, Kim SB, Ko SY, Song DS. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis. Gut Liver 2019;13:191-6. [PMID: 30400729 DOI: 10.5009/gnl18240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Yu JH, Lee JI, Lee KS, Kim JK. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C. Virol J 2017;14:164. [PMID: 28836992 DOI: 10.1186/s12985-017-0826-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Shin SK, Lee JW, Ra H, Kwon OS, Shin JB, Jin YJ, Lee S, Han KJ, Kim YN, Kim TH, Kim YS, Kim JH. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study. J Korean Med Sci 2019;34:e264. [PMID: 31650719 DOI: 10.3346/jkms.2019.34.e264] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Sung PS, Lee EB, Park DJ, Lozada A, Jang JW, Bae SH, Choi JY, Yoon SK. Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling. Clin Mol Hepatol. 2018;24:302-310. [PMID: 29526079 DOI: 10.3350/cmh.2017.0074] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
12 Jung YS, Kim NH, Park JH, Park DI, Sohn CI. Correlation between Hepatitis B Virus Infection and Colorectal Neoplasia. J Clin Med 2019;8:E2085. [PMID: 31805669 DOI: 10.3390/jcm8122085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK. Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. Gut Liver 2019;13:549-56. [PMID: 30970433 DOI: 10.5009/gnl18432] [Reference Citation Analysis]
14 Lee HW, Yoo KY, Won JW, Kim HJ. Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. Gut Liver 2017;11:721-7. [PMID: 28874040 DOI: 10.5009/gnl17209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kawabe N, Hashimoto S, Yoshioka K. Editorial: comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C. Aliment Pharmacol Ther 2019;49:116-7. [PMID: 30548317 DOI: 10.1111/apt.15051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
17 Sinn DH, Cho EJ, Kim JH, Kim DY, Kim YJ, Choi MS. Current status and strategies for viral hepatitis control in Korea. Clin Mol Hepatol 2017;23:189-95. [PMID: 28942620 DOI: 10.3350/cmh.2017.0033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
18 Ran M, Huang J, Liang H, Jiang J, Liang B, Ning C, Zang N, Liao W, Liu H, Qin F, Yang Q, Ho W, Ye L, Chen H. Alcohol attenuates anti-HCV function of IFN-λ1 through up-regulation of PLASy expression in human hepatic cells. J Med Virol 2018;90:1112-20. [PMID: 29446489 DOI: 10.1002/jmv.25053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Choi GH, Jang ES, Kim JW, Jeong SH. A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea. Gut Liver 2020;14:808-16. [PMID: 32066209 DOI: 10.5009/gnl19296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kim JM, Lee KW, Sinn DH, Choi GS, Yi NJ, Kwon CHD, Suh KS, Joh JW. Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience. Ann Surg Treat Res 2018;95:147-51. [PMID: 30182021 DOI: 10.4174/astr.2018.95.3.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Nam JY, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Bae SH, Ki M, Choi HY, Lee EY, Jeong SH. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study. Gut Liver 2020;14:207-17. [PMID: 31158950 DOI: 10.5009/gnl19005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
22 Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, Lee BS, Jeong SH. Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era. Gut Liver 2017;11:543-50. [PMID: 28506027 DOI: 10.5009/gnl16530] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
23 Han JW, Sung PS, Kim KH, Hong SH, Shin EC, Jun Song M, Park SH. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection. J Infect Dis 2019;220:1290-301. [PMID: 31152667 DOI: 10.1093/infdis/jiz291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
24 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
25 Kim T, Kim J. Factors Associated with Hepatitis C Antibody Positivity in Korean Adults: A Cross-Sectional Study Based on 2013-2018 Korea National Health and Nutrition Examination Survey. Healthcare (Basel) 2021;9:1366. [PMID: 34683045 DOI: 10.3390/healthcare9101366] [Reference Citation Analysis]
26 Lim DH, Jeong JY, Nam S, Choi J, Kwon HC, Yoon YB, Kim Y, Chin B. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea. J Korean Med Sci 2021;36:e308. [PMID: 34845874 DOI: 10.3346/jkms.2021.36.e308] [Reference Citation Analysis]
27 Chang YK, Tseng YT, Chen KH, Chen KT. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan. BMC Endocr Disord 2019;19:36. [PMID: 30953492 DOI: 10.1186/s12902-019-0362-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 So IT, Lee YJ, Jung HI, Hwang JS, Jang BK. The quality of non-alcoholic fatty liver disease information resources for patients on the internet in Korea. Korean J Intern Med 2021;36:86-96. [PMID: 31362471 DOI: 10.3904/kjim.2018.359] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Yeon JE. Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. Clin Mol Hepatol 2018;24:278-93. [PMID: 29716179 DOI: 10.3350/cmh.2018.1002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
30 Lee YB, Nam JY, Lee JH, Chang Y, Cho H, Cho YY, Cho EJ, Yu SJ, Kim HY, Lee DH, Lee JM, Hwang SG, Kim YJ, Yoon JH. Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Sci Rep 2018;8:13651. [PMID: 30209336 DOI: 10.1038/s41598-018-31839-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Ko SY, Choe WH. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. Clin Mol Hepatol 2018;24:351-7. [PMID: 29544240 DOI: 10.3350/cmh.2017.0063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Seo KI, Yun BC, Li WJ, Lee SU, Han BH, Park ET. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study. Clin Mol Hepatol 2017;23:74-9. [PMID: 28259115 DOI: 10.3350/cmh.2016.0052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
33 Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test. J Med Virol 2019;91:2158-65. [PMID: 31452206 DOI: 10.1002/jmv.25575] [Reference Citation Analysis]
34 Ahn SH, Choe WH, Kim YJ, Heo J, Latarska-Smuga D, Kang J, Paik SW. Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C. Gut Liver 2020;14:368-76. [PMID: 31533395 DOI: 10.5009/gnl18100] [Reference Citation Analysis]
35 Kim YM, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB, Song MJ, Jang JW, Ko SY, Lee JD. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Clin Mol Hepatol 2018;24:311-8. [PMID: 29865774 DOI: 10.3350/cmh.2017.0070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
36 Yoo SH, Kwon JH, Nam SW, Kim HY, Kim CW, You CR, Choi SW, Cho SH, Han JY, Song DS, Chang UI, Yang JM, Lee HL, Lee SW, Han NI, Kim SH, Song MJ, Hwang S, Sung PS, Jang JW, Bae SH, Choi JY, Yoon SK. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients. J Viral Hepat 2018;25:1189-96. [PMID: 29660199 DOI: 10.1111/jvh.12918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
38 Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore). 2017;96:e5321. [PMID: 28072684 DOI: 10.1097/md.0000000000005321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
39 Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Aliment Pharmacol Ther 2018;48:1290-300. [PMID: 30362139 DOI: 10.1111/apt.15011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
40 Fang S, Su J, Liang B, Li X, Li Y, Jiang J, Huang J, Zhou B, Ning C, Li J, Ho W, Li Y, Chen H, Liang H, Ye L. Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells. Sci Rep 2017;7:44039. [PMID: 28276509 DOI: 10.1038/srep44039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
41 Chung W, Kim KA, Jang ES, Ki M, Choi HY, Jeong SH. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea. J Gastroenterol Hepatol 2019;34:776-83. [PMID: 30462841 DOI: 10.1111/jgh.14554] [Reference Citation Analysis]
42 Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905 [PMID: 29209131 DOI: 10.3748/wjg.v23.i44.7899] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
43 Sinn DH, Kang D, Hong YS, Koh KC, Guallar E, Cho J, Gwak GY. Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. PLoS One 2021;16:e0255624. [PMID: 34343200 DOI: 10.1371/journal.pone.0255624] [Reference Citation Analysis]
44 Kwon JH, Yoo SH, Nam SW, Kim HY, Kim CW, You CR, Choi SW, Cho SH, Han JY, Song DS, Chang UI, Yang JM, Lee SW, Lee HL, Han NI, Kim SH, Song MJ, Sung PS, Jang JW, Bae SH, Choi JY, Yoon SK. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. J Med Virol 2019;91:1104-11. [PMID: 30695109 DOI: 10.1002/jmv.25412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 Ok KS, Jeong SH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Bae SH, Lee HC. The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study. Medicine (Baltimore) 2016;95:e4594. [PMID: 27583874 DOI: 10.1097/MD.0000000000004594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
46 Jeong SH, Jang ES, Choi HY, Kim KA, Chung W, Ki M. Current status of hepatitis C virus infection and countermeasures in South Korea. Epidemiol Health 2017;39:e2017017. [PMID: 28774165 DOI: 10.4178/epih.e2017017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
47 Shin SR, Kim YS, Lim YS, Lee JS, Lee JW, Kim SM, Jeong SH, Sohn JH, Lee MS, Park SH. Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study. Gut Liver 2017;11:270-5. [PMID: 27728965 DOI: 10.5009/gnl16163] [Reference Citation Analysis]
48 Lee JH, Cho J, Kim YJ, Im SH, Jang ES, Kim JW, Kim HB, Jeong SH. Occupational blood exposures in health care workers: incidence, characteristics, and transmission of bloodborne pathogens in South Korea. BMC Public Health 2017;17:827. [PMID: 29047340 DOI: 10.1186/s12889-017-4844-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
49 Kim DY, Wong G, Lee J, Kim MH, Smith N, Blissett R, Kim HJ. Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea. Curr Med Res Opin 2020;36:993-1002. [PMID: 32295431 DOI: 10.1080/03007995.2020.1756232] [Reference Citation Analysis]
50 Sung PS, Hong SH, Chung JH, Kim S, Park SH, Kim HM, Yoon SK, Shin EC. IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection. Sci Rep 2017;7:3821. [PMID: 28630501 DOI: 10.1038/s41598-017-04186-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
51 Ki M, Choi HY, Kim KA, Jang ES, Jeong SH. Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data. Gut Liver 2017;11:835-42. [PMID: 28798283 DOI: 10.5009/gnl17034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
52 Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH. Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. Gut Liver 2020;14:775-82. [PMID: 32000468 DOI: 10.5009/gnl19260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Choi IS, Kim KM, Shim SG. Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study. Arab J Gastroenterol 2021;22:23-7. [PMID: 33223391 DOI: 10.1016/j.ajg.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Cho BW, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. Clin Mol Hepatol. 2017;23:51-56. [PMID: 28297836 DOI: 10.3350/cmh.2016.0053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]